Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 95

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 95
---
 ~5% |

| - | Resistant infections: ~91,000 cases annually |

| - | Estimated treatment cost per patient: $600 |

| - | U.S. TAM = ~$55 million per year |

Global Case

| - | Resistance rates are higher in Asia and parts of Europe. |

| - | Conservative multiplier: 4× U.S. TAM |

| - | Global TAM ≈ $220 million per year |

Thus, we estimate that $220 million represents
the maximum revenue ceiling assuming full penetration of all diagnosed resistant gonorrhea cases worldwide.

<div align='center'>59</div>

Serviceable Obtainable Market (SOM) – Ceftriaxone-Resistant Gonorrhea

The Serviceable Obtainable Market (SOM) represents
the realistic portion of the global patient pool that can be accessed and captured by our therapy, accounting for geography, regulatory
pathways, healthcare access, and competitive penetration.

Launch strategies in infectious disease markets
typically achieve 20–40% penetration in high-need segments over five years. We conservatively assume 30% global market share capture.

Patient SOM

| - | Global resistant infections: ~364,000 cases/year (based on 4× 
 U.S. burden)                                                  |

| - | 30% capture represents approximately 110,000 patients annually |

| - | U.S. contribution alone: ~27,000 patients (~$17M in revenue) |

Revenue SOM

| - | 30% of $220M global market = ~$66–70M/year |

SOM reflects a tangible, realistic revenue
line, not the theoretical ceiling (TAM).

Even at 30% penetration, the opportunity is
substantial and defensible due to:

| - | Lack of effective alternative therapies for resistant gonorrhea |

| - | High clinical urgency and CDC/WHO surveillance prioritization |

| - | Concentrated patient pools in developed markets with strong reimbursement 
 systems                                                                   |

Final SOM Opportunity

~110,000 patients/year treatable

~$70M/year realistic revenue potential at
30% global penetration of the addressable market for Ceftriaxone-Resistant Gonorrhea

These estimates are illustrative only and based on assumptions regarding TAM/SAM/SOM, pricing and epidemiology. . Our product candidate is still in preclinical development and has
not been approved by any regulatory authority. We do not yet know the final dosage, or number of injections required per treatment course